4.7 Article

Structure-Based Discovery of Novel Chemotypes for Adenosine A2A Receptor Antagonists

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 4, Pages 1799-1809

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm901647p

Keywords

-

Funding

  1. National Institutes of Health [GM071872, GM074832, GM074961]
  2. Oulu Biocenter
  3. Sigrid Joselius Foundation
  4. FP7 Marie Curie European Reintegration
  5. Dutch Top Institute Pharma (TIPharma) [D1-105]

Ask authors/readers for more resources

The recent progress in crystallography of G-protein coupled receptors Opens an unprecedented venue for structure-based GPCR drug discovery. To test efficiency of the structure-based approach, we performed molecular docking and virtual ligand screening (VLS) of more than 4 million commercially available drug-like and lead-like compounds against the A(2A)AR 2.6 angstrom resolution crystal structure. Out of 56 high ranking compounds tested in A(2A)AR binding assays, 23 showed affinities under 10 mu M, 11 of those had sub-mu M affinities and two compounds had affinities under 60 nM. The identified hits represent at least 9 different chemical scaffolds and are Characterized by very high ligand efficiency (0.3-0.5 kcal/mol per heavy atom). Significant A(2A)AR antagonist activities were confirmed for 10 out of 13 ligands tested in Functional assays. High success rate, novelty, and diversity of the chemical scaffolds and strong ligand efficiency of the A(2A)AR antagonists identified in this study suggest practical applicability of receptor-based VLS in GPCR drug discovery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available